FDA Approves Belzutifan Plus Lenvatinib for Advanced Clear Cell Kidney Cancer After a PD-1 Inhibitor. Overall Survival Did Not Reach Significance.
The Food and Drug Administration approved belzutifan with lenvatinib on Sept. 24 for clear cell RCC after PD-1 or PD-L1 therapy. In LITESPARK-011, median progression-free survival was 14.6 vs 10.6 months against cabozantinib, but final overall survival was not statistically significant.
On Sept. 24, the Food and Drug Administration approved belzutifan (Welireg, Merck) with lenvatinib (Lenvima, Eisai) for adults with advanced renal cell carcinoma with a clear cell component who have already received a PD-1 or PD-L1 inhibitor. Merck and Eisai described it as the first approved combination of a HIF-2 alpha inhibitor and a multi-targeted VEGFR tyrosine kinase inhibitor for these patients.
The approval rests on one open-label trial with a split result. Progression-free survival and response rate favored the combination. The final overall survival analysis did not reach statistical significance.
What the trial showed
According to the FDA's announcement, LITESPARK-011 (NCT04586231) was an open-label, randomized, active-controlled trial in 747 patients whose locally advanced or metastatic clear cell disease progressed on or after a PD-1 or PD-L1 inhibitor, or within six months of finishing adjuvant PD-1 therapy. Patients were randomized 1:1 to belzutifan plus lenvatinib or to cabozantinib.
Median progression-free survival by blinded independent central review was 14.6 months with the combination and 10.6 months with cabozantinib (hazard ratio 0.74, 95% CI 0.61 to 0.89). Objective response rate was 53 percent versus 40 percent.
Median overall survival was 33.7 months versus 28.6 months (HR 0.85, 95% CI 0.70 to 1.03). The FDA described the final analysis as not statistically significant. The point estimate favors the combination, but the confidence interval includes no difference.
A four-month gain in median progression-free survival is a real finding. The final survival analysis did not confirm a survival advantage, and the trial was open-label.
How to read the result
Cabozantinib is a reasonable comparator in this setting, but it is one of several options after checkpoint inhibitor therapy, and the trial did not compare the combination with the others. Blinded central review limits bias in assessing progression. It does not remove the effect of open-label treatment on dose changes, discontinuations and later therapy.
Readers who saw the February data should note that the numbers differ. Urology Times reported a progression-free survival hazard ratio of 0.70 and an overall survival hazard ratio of 0.85 (95% CI 0.68 to 1.05) from the second interim analysis, presented at the 2026 ASCO Genitourinary Cancers Symposium. The figures above come from the later analyses cited in the FDA announcement.
Safety and the label
Belzutifan carries a boxed warning for embryo-fetal toxicity and warnings for anemia and hypoxia; for the combination, warnings also include cardiac dysfunction. The lenvatinib label adds its own list, including hypertension, arterial thromboembolic events, hepatotoxicity, proteinuria, hemorrhage and QT prolongation. The recommended dosage is belzutifan 120 mg with lenvatinib 20 mg once daily until progression or unacceptable toxicity.
The companies' announcement reports that fatal adverse reactions occurred in 5 percent of patients on the combination, most often sepsis, pneumonia, pneumonitis and respiratory failure. Adverse reactions led to permanent discontinuation of belzutifan in 17 percent and lenvatinib in 23 percent.
What it means in clinic
For oncologists, the choice after a PD-1 inhibitor now includes a regimen with longer median progression-free survival than cabozantinib and no proven survival benefit, at the cost of a two-drug toxicity profile. That trade-off is worth stating plainly when discussing options. It sits alongside other recent approvals built on progression-free survival, such as tucatinib maintenance in HER2-positive breast cancer.
For referring and co-managing physicians, the label points to what needs watching: hemoglobin, oxygen saturation, blood pressure, cardiac function and contraception in patients who can become pregnant. The FDA announcement does not give monitoring intervals, so check the full prescribing information on Drugs@FDA.
Reported, fact-checked and edited by The Script Pad's editorial staff.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
